Happy birthday to jirikido and rosefox!
Hello to new reader sweetcharity!
Well, this is a change. Usually on new-doctor days, I'm inexplicably fit as a fiddle. Today? Hobbling around like an octogenarian. Yay?
Despite misinformation, Diesel is open today. So saith liamstliam, and I doubt not his veracity. We'll be coming over a little later than usual - my appointment is at 4:15 - but we will be there.
Cold Spring Harbor Laboratory (CSHL) researchers led by Daniel Nolan and Assistant Professor Vivek Mittal have found that bone marrow (BM) derived endothelial progenitor cells (EPCs) play a critical role in the early stages of tumor progression and that eliminating EPCs stops cancer growth. Using sophisticated high-resolution microscopy and flow cytometry, they zeroed in on the earliest stages of cancer progression and identified the role of EPCs in generating blood vessels that allow cancers to grow. "If we selectively blocked the EPCs, tumors were unable to make blood vessels and could not sustain their own growth," said Vivek Mittal, CSHL Assistant Professor.
The findings open an entirely new field of research on how vascular progenitor cells control tumor growth and underscore their potential for cancer therapeutics. Published on June 15, 2007 in Genes & Development, the CSHL study settles a dispute in the field of angiogenesis that has resulted from years of inconsistent findings about the existence of EPCs in cancer tumors. Until now, this field of research that focuses on new blood vessel development has been split between researchers who have suggested the existence of EPCs and those who have vehemently disputed their presence.
The CSHL research posits that those who did not find evidence of EPCs in tumors were probably looking for them in later stages of tumor progression when EPCs are diluted by host endothelial cells. The new results show that EPCs are only present in the earliest stages of tumor progression, before the formation of blood vessels. "We found that the role of EPCs is to direct the formation and organization of the vascular structure that ultimately feeds the tumor as it grows," said CSHL researcher Daniel Nolan.
Bat, Albrecht Dürer.: Dusty amber, grey musk, red orchid, moonflower, night-blooming phlox, stock, honeysuckle, English ivy, toadflax, and purple salvia.
In bottle: Dusty amber. How perfectly descriptive. This is a fuzzy bat!
On me: And it becomes a sweet floral with those dusty grey underpinnings. Spooky, you'll like this one. :)
Cleopatra Testing Poisons on Those Condemned to Death, Alexandre Cabanel.: Accords of peach kernel, hemlock, aconite, and belladonna, with bitter almond, saffron, honey, myrrh, hyssop, frankincense, and palm.
In bottle: Oh, man. Saffron. And honey. And myrrh.
On me: This is a thick scent. Ground with a mortar and pestle. Spiky notes of interest. All tied together with the honey...
Kiyohime Changes From a Serpent, Yoshitoshi.: Salty ocean spray, red kelp, black plum, lychee, sea moss, green musk, hachiya, plum blossom, and matcha.
In bottle: Salt spray and sweet fruits. :)
On me: An ocean scent that works... like Yemaya, but with plum and lychee instead of melon. :)
Love and Pain, Edvard Munch.: Lavender, Balkan tobacco, black musk, dark vanilla, and golden copaifera.
In bottle: Spiky herbal lavender.
On me: A slightly more muted lavender. Will see how it develops.